Alpharma Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ALPHARMA, and when can generic versions of ALPHARMA drugs launch?
ALPHARMA has sixty-three approved drugs.
There are nine US patents protecting ALPHARMA drugs.
There are fifty-five patent family members on ALPHARMA drugs in twenty-three countries and seven supplementary protection certificates in three countries.
Summary for Alpharma
| International Patents: | 55 |
| US Patents: | 9 |
| Tradenames: | 45 |
| Ingredients: | 42 |
| NDAs: | 63 |
Drugs and US Patents for Alpharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alpharma Us Pharms | FLURANDRENOLIDE | flurandrenolide | LOTION;TOPICAL | 087203-001 | Apr 29, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Alpharma Pharms | EMBEDA | morphine sulfate; naltrexone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022321-002 | Aug 13, 2009 | DISCN | Yes | No | 8,158,156 | ⤷ Sign Up | ⤷ Sign Up | ||||
| Alpharma Pharms | EMBEDA | morphine sulfate; naltrexone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022321-002 | Aug 13, 2009 | DISCN | Yes | No | 7,682,634 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Alpharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Alpharma Us Pharms | SERAX | oxazepam | CAPSULE;ORAL | 015539-006 | Approved Prior to Jan 1, 1982 | 4,620,974 | ⤷ Sign Up |
| Alpharma Us Pharms | SERAX | oxazepam | CAPSULE;ORAL | 015539-004 | Approved Prior to Jan 1, 1982 | 4,620,974 | ⤷ Sign Up |
| Alpharma Pharms | EMBEDA | morphine sulfate; naltrexone hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 022321-003 | Aug 13, 2009 | 5,378,474 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ALPHARMA drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Capsules | 100 mg/4 mg | ➤ Subscribe | 2010-05-03 |
| ➤ Subscribe | Extended-release Capsules | 60 mg/2.4 mg | ➤ Subscribe | 2010-05-25 |
| ➤ Subscribe | Extended-release Capsules | 30 mg/1.2 mg, 50 mg/2 mg and 80 mg/3.2 mg | ➤ Subscribe | 2010-05-28 |
International Patents for Alpharma Drugs
Supplementary Protection Certificates for Alpharma Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0809498 | SPC/GB10/012 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112 |
| 1581193 | SPC/GB12/047 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: DEXAMETHASONE; REGISTERED: UK EU/1/10/638/001 20100727 |
| 2233112 | 132014902285293 | Italy | ⤷ Sign Up | PRODUCT NAME: FLUOCINOLONE ACETONIDE(ILUVIEN); AUTHORISATION NUMBER(S) AND DATE(S): 042616019, 20140530;PL27813/0001, 20120504 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
